Welcome to our dedicated page for Harvard Biosci SEC filings (Ticker: HBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Harvard Bioscience filings document regulatory disclosures for a life science research tools company with Cellular and Molecular Technologies and Preclinical product families. Form 8-K reports cover operating results, preliminary financial information, corporate presentations, restructuring and manufacturing consolidation actions, executive employment agreements, and stockholder votes affecting the company’s common stock.
Proxy statements describe board matters, executive compensation, pay-versus-performance data, equity awards, charter amendments and special-meeting proposals, including reverse stock split authority and related voting results. The filings also frame governance, capital-structure and forward-looking disclosure topics tied to the company’s global sales channels and manufacturing footprint.
Eade Katherine A. reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Katherine A. Eade received an award of 16,556 restricted stock units of common stock at no cost. The RSUs vest in full either immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first. After this grant, she beneficially owns 58,669 shares, including 42,113 shares of common stock adjusted for a 10-for-1 reverse stock split that took effect on March 13, 2026.
Snider William reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director William Snider received an equity grant in the form of 16,556 restricted stock units of common stock. The award vests in full immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first, providing time-based compensation for board service.
After this grant, Snider holds a total of 48,556 common share equivalents, including the new award, previously purchased common shares from March 16 and March 17, 2026, and 11,000 restricted stock units scheduled to fully vest on December 17, 2026. The filing also notes that the 11,000 restricted stock units were adjusted to reflect a 10-for-1 reverse stock split that took place on March 13, 2026.
DENELSKY STEPHEN J reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Stephen J. Denelsky received a grant of 16,556 restricted stock units (RSUs) of common stock. The award vests in full either immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first.
After this award, Denelsky holds 37,556 shares and RSUs in total, including 10,000 shares of common stock purchased on March 17, 2026 and 11,000 RSUs scheduled to fully vest on September 5, 2026. The filing notes that these 11,000 RSUs were adjusted to reflect a 10-for-1 reverse stock split that took place on March 13, 2026.
Gagnon Robert E. reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Robert E. Gagnon received an equity grant of 16,556 restricted stock units (RSUs) of common stock. The award vests in full immediately before the company’s next annual meeting or one year from the grant date, whichever occurs first.
After this grant, Gagnon beneficially owns 27,556 common shares, including 11,000 shares previously issued upon vesting of earlier RSUs. Those 11,000 shares were adjusted to reflect a 10-for-1 reverse stock split of Harvard Bioscience common stock that took place on March 13, 2026.
Benson Seth Benjamin reported acquisition or exercise transactions in this Form 4 filing.
Harvard Bioscience director Seth Benjamin Benson received a grant of 16,556 restricted stock units of common stock, awarded at a price of $0.0000 per share. This equity award will vest in full immediately before the company’s next annual meeting or one year from the grant date, whichever comes first.
After this grant, Benson directly holds 27,556 shares of common stock, including the new award and 11,000 shares already beneficially owned. The filing also notes a 10-for-1 reverse stock split of Harvard Bioscience common stock that occurred on March 13, 2026, which adjusted previously reported award amounts.
Harvard Bioscience, Inc. reported results of its 2026 Annual Meeting of Stockholders. Stockholders approved an Amended and Restated 2021 Incentive Plan that increases the shares of common stock reserved for equity awards by 400,000 shares, on top of 646,520 shares that were available for future awards as of December 31, 2025.
Stockholders also approved an amendment to the Employee Stock Purchase Plan to increase authorized shares for employee purchases, elected two Class II directors to terms ending in 2029, ratified Grant Thornton LLP as independent auditor for 2026, and backed executive compensation in a non-binding advisory vote.
Harvard Bioscience reported a Schedule 13G/A amendment showing that Adam M. Hutt, as Managing Member of Leviticus Partners, beneficially owns 293,676 shares of Common Stock, representing 6.5% of the class. The filing lists sole voting and sole dispositive power over those shares.
The document provides the filer’s and issuer’s addresses and the CUSIP 416906105. A signature line shows the amendment signed on 05/14/2026.
Harvard Bioscience reported first-quarter 2026 revenue of $20.8 million, down about 5% from the prior year as academic and Asia-Pacific demand softened. Gross profit held steady at $12.2 million, with gross margin improving to 59.0% from 56.0% on a more favorable product mix.
The company posted a net loss of $3.4 million, far smaller than the prior-year loss that was dominated by a large goodwill impairment. Operating expenses declined sharply without that charge, but interest expense nearly doubled to $1.7 million following the high-rate 2025 loan refinancing.
Cash and cash equivalents were $7.1 million against $40 million of term debt, and the company remained in compliance with liquidity and adjusted EBITDA covenants. Management states prior going concern doubts have been alleviated. A 1-for-10 reverse stock split was completed to support Nasdaq listing compliance, and the new Project Viking manufacturing consolidation is expected to deliver several million dollars of annual cost savings after 2027, with restructuring charges incurred beginning in this quarter.
Harvard Bioscience, Inc. furnished an investor presentation outlining its strategy, recent refinancing and financial outlook. The company reported FY25 revenue of $87M with 54% recurring revenue and $8M adjusted EBITDA, and is guiding FY26 revenue growth of 2–4%, adjusted EBITDA growth of 6–10%, and an adjusted gross margin of 58–60%. A debt refinancing extends maturity to December 2029, adds a $7M convertible Term C loan at $10.00/share with automatic conversion above $15.00, and is expected to reduce annual debt service by $3M. The company plans to close its Holliston, MA plant under “Project Viking,” consolidating manufacturing and targeting $3M of adjusted EBITDA improvement in 2027 and $4M from 2028 onward.
Harvard Bioscience reported mixed first-quarter 2026 results. Revenue was $20.8 million versus $21.8 million a year earlier, while gross margin improved to 59% from 56% as the company shifted toward higher-margin products such as organoid platforms and BTX Electroporation and SoHo Telemetry systems.
Net loss narrowed sharply to $3.4 million from $50.3 million, which previously included a $48.0 million goodwill impairment. Adjusted EBITDA was $0.8 million, unchanged from last year, and adjusted EBITDA margin held at 3.7%. Operating cash flow moved from $3.0 million provided to $0.7 million used, largely due to one-time costs tied to debt refinancing.
Management said first-quarter revenue was in line with expectations, reaffirmed full-year 2026 guidance, and projected mid–single-digit revenue growth, margin expansion, and continued adjusted EBITDA profitability in the second quarter as new product adoption scales.